Posted by Michael Wonder on 18 Jan 2022
Gilead withdraws use of Zydelig to treat two types of cancer
14 January 2022 - Gilead Sciences on Friday notified the U.S. health regulator of its decision to voluntarily withdraw the use of its drug Zydelig for two types of cancer - follicular lymphoma and small lymphocytic leukaemia.
The U.S. Food and Drug Administration gave the drug an accelerated approval in 2014 to treat relapsed follicular B-cell non-Hodgkin lymphoma and relapsed small lymphocytic leukaemia along with relapsed chronic lymphocytic leukaemia.
